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Drosophila Armadillo and its mammalian homologue b-catenin are scaffolding proteins involved
in the assembly of multiprotein complexes with diverse biological roles. They mediate adherens
junction assembly, thus determining tissue architecture, and also transduce Wnt/Wingless inter-
cellular signals, which regulate embryonic cell fates and, if inappropriately activated, contribute
to tumorigenesis. To learn more about Armadillo/b-catenin’s scaffolding function, we examined
in detail its interaction with one of its protein targets, cadherin. We utilized two assay systems: the
yeast two-hybrid system to study cadherin binding in the absence of Armadillo/b-catenin’s other
protein partners, and mammalian cells where interactions were assessed in their presence. We
found that segments of the cadherin cytoplasmic tail as small as 23 amino acids bind Armadillo
or b-catenin in yeast, whereas a slightly longer region is required for binding in mammalian cells.
We used mutagenesis to identify critical amino acids required for cadherin interaction with
Armadillo/b-catenin. Expression of such short cadherin sequences in mammalian cells did not
affect adherens junctions but effectively inhibited b-catenin–mediated signaling. This suggests that
the interaction between b-catenin and T cell factor family transcription factors is a sensitive target
for disruption, making the use of analogues of these cadherin derivatives a potentially useful
means to suppress tumor progression.
INTRODUCTION
Vertebrate b-catenin and its Drosophila homologue Arma-
dillo (Arm) play critical roles in both cell adhesion and
signal transduction (reviewed by Gumbiner, 1996; Willert
and Nusse, 1998). These proteins are key effectors of Wing-
less (Wg)/Wnt signal transduction, interacting with DNA-
binding proteins of the TCF/LEF family to form bipartite
transcription factors that activate Wnt responsive genes (re-
viewed by Wodarz and Nusse, 1998). b-Catenin and Arm
are also core components of the cadherin-catenin complex,
which mediates cell-cell adhesion at adherens junctions and
connects these junctions to the actin cytoskeleton (reviewed
by Ben-Ze’ev and Geiger, 1998; Provost and Rimm, 1999).
These quite distinct biological functions of b-catenin/Arm
most probably rest on a similar biochemical role: b-catenin/
Arm mediates assembly of multiprotein complexes. Thus, in
adherens junctions, it simultaneously binds cadherins and
a-catenin, whereas in the nucleus it links TCF/LEF proteins
to the basal transcriptional machinery (reviewed by Zhurin-
sky et al., 2000a).
In addition to these roles in normal development and
physiology, b-catenin is also a critical target in the develop-
ment of a variety of human tumors (reviewed by Peifer and
Polakis, 2000). In normal cells, b-catenin/Arm’s role in sig-
nal transduction is kept off by targeting the protein for rapid
proteolytic destruction. b-Catenin/Arm is targeted for de-
struction by a multiprotein complex, which includes two
scaffolding proteins, APC and axin/conductin, and a kinase,
GSK3b. Assembly of this complex leads to phosphorylation
of b-catenin/Arm, and its subsequent ubiquitination and
destruction. If this complex is disrupted by mutations in
either APC (reviewed by Peifer and Polakis, 2000) or axin/
conductin (Liu et al., 2000; Satoh et al., 2000) the Wnt path-
way is activated. This can lead to cell proliferation and
tumor initiation. Finally, b-catenin binds to a diverse set of
other proteins, including the presenilins, the epidermal
growth factor (EGF) receptor, the actin-binding protein fas-
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cin, and the transcription factor Teashirt (reviewed by
Zhurinsky et al., 2000a). In most of these cases, the function
of the interaction remains a mystery.
To understand the roles b-catenin/Arm plays in embry-
onic development and oncogenesis, we must understand in
detail how it functions as a scaffold. Furthermore, if we
understood in molecular detail how b-catenin/Arm binds to
individual partners, we might be able to use this information
to design inhibitors that could interfere with b-catenin’s
interaction with individual partners. For example, a specific
inhibitor of the b-catenin/TCF interaction might hold prom-
ise as a therapeutic agent in colorectal and other types of
cancer. b-Catenin/Arm protein is composed of a series of
protein-protein interaction motifs that allow it to function as
a scaffold. The N-terminal domain contains the binding site
for a-catenin, as well as phosphorylation sites recognized by
GSK3b, whereas the C terminus contains the transcriptional
activation domain and the binding site for Teashirt (re-
viewed by Zhurinsky et al., 2000a). The central two thirds of
b-catenin/Arm is composed of twelve 42-amino acid Arm
repeats. Many partners bind to this region, including TCF/
LEF, cadherins, APC, and axin. Because these latter partners
play key roles in cell adhesion, Wnt signaling, or the de-
struction complex, their interactions with b-catenin/Arm
have been studied in some detail. These studies examined
which regions of b-catenin/Arm are sufficient for binding to
the partner and also which region of the partners are suffi-
cient for binding to b-catenin/Arm. In each case, the mini-
mum region of the partner that is sufficient for interaction
with b-catenin/Arm is relatively small. The minimal frag-
ments thus far tested range from 70 amino acids for mam-
malian E- or N-cadherin (Sadot et al., 1998), 41 amino acids
for Drosophila E-cadherin (DE-cadherin; Pai et al., 1996), 31
amino acids for Drosophila APC2 (McCartney et al., 1999), 17
amino acids for mammalian LEF-1 (von Kries et al., 2000),
and 25 amino acids for human axin (Nakamura et al., 1998).
When the interacting regions of cadherins, TCF/LEF, and
APC are aligned, there is only modest sequence similarity,
although all are rich in acidic amino acids and serines.
Phosphorylation of these serines, as is thought to happen in
APC (Rubinfeld et al., 1996), axin (Jho et al., 1999) and cad-
herin (Stappert and Kemler, 1994; Lickert et al., 2000), would
increase the net negative charge further. This charge distri-
bution is intriguing in light of the structure of b-catenin
(Huber et al., 1997). The Arm repeats form a superhelix, with
a large groove on the surface lined by basic amino acids. In
another Arm repeat protein, the nuclear localization signal
receptor, the nuclear localization signal peptide binds in an
extended conformation in the groove (Conti et al., 1998).
Previous mutational studies of b-catenin/Arm partners
have begun to define the sequence requirements for binding.
Mutation of three conserved serines in one of the 20-amino
acid b-catenin-binding sites of human APC reduced the
ability of the mutated fragment to down-regulate b-catenin
levels, suggesting reduced binding to b-catenin (Rubinfeld
et al., 1997). Clustered point mutations in LEF-1 (Hsu et al.,
1998; von Kries et al., 2000) and TCF4 (Omer et al., 1999)
identified critical amino acids that are either required for
binding or contribute to it. Mutational analysis of the b-cate-
nin-binding site in E-cadherin focused on a series of serine
residues that are phosphorylated in vivo (Stappert and Kem-
ler, 1994; Lickert et al., 2000). Mutation of individual serines
had a modest effect on binding, whereas mutation of all
eight conserved serines abolished binding in vivo.
These data suggest a testable model for the interaction
between b-catenin/Arm and its partners, in which charge-
based and other interactions mediate the binding between
the Arm repeats of b-catenin/Arm and short regions of its
partner proteins, potentially binding as extended peptides in
the basic Arm repeat groove. Here, we test this model for the
interaction between b-catenin/Arm and its partners, by car-
rying out a detailed analysis of the sequence requirements
for interaction between cadherins and b-catenin/Arm.
MATERIALS AND METHODS
Cadherin Constructs and Yeast Two-Hybrid
Experiments
The Arm R1–12 construct in pCK2 was described by Pai et al. (1996;
it was previously called Arm R1–13, but the subsequent crystal
structure of b-catenin led to reassessment of repeat number and
boundaries). Similar constructs containing Arm repeats 2–10
(ArmR2–10: amino acids 177–596) and the corresponding fragments
of mouse b-catenin (R1–12: amino acids 119–708; R2–10: amino
acids 169–583) were generated for this work. DE-cadherin frag-
ments were generated by polymerase chain reaction (PCR) with
flanking BamHI and EcoRI restriction sites and cloned into pCK4
(Pai et al., 1996). The amino acids included in each fragment are
diagrammed in Figure 1, A and B. All constructs included a stop
codon after the final amino acid of DE-cadherin. All clones were
sequenced in their entirety to confirm their sequence. The DE-
cadherin mutants (DEC) were generated by a two-step PCR proce-
dure. Primers for each strand containing the desired mutant se-
quence were used in two separate PCR reactions with flanking
primers to amplify the N- and C-terminal portions of the DE-
cadherin cytoplasmic domain. Products from these two reactions
were mixed and used as a template for another PCR reaction con-
taining only the flanking primers. This reaction generated a full-
length DE-cadherin cytoplasmic domain with flanking BamHI and
EcoRI sites containing the desired mutations, which was cloned into
pCK4. Mutation DECM2 was introduced into the smaller DEC30
fragment by amplifying the relevant portion of the longer mutant
clone with DEC30 primers. All mutations were confirmed by se-
quencing and are diagrammed in Figure 6A. Two-hybrid assays
were performed as described by Pai et al. (1996). Arm or b-catenin
fragments were fused to the LexA DNA-binding domain in pCK2,
and DE-cadherin fragments were fused to the Gal4 activation do-
main in pCK4. The two plasmids were transformed simultaneously
into the yeast strain L40. b-Galactosidase values are the averages
from duplicate assays performed on at least three independent
transformants.
Cell Lines and Transfections
Chinese hamster ovary (CHO), 293T and MDCK cells were main-
tained in DMEM with 10% calf serum. Transient transfections with
Drosophila E-cadherin (DEC) constructs were carried out using the
calcium phosphate precipitation method with 293T cells and by
Lipofectamine (GIBCO, Grand Island, NY) with CHO cells. For
recloning the various mutant DEC sequences from the pCK4 plas-
mid into the pEGFP-C1 plasmid (Clontech, Palo Alto, CA), the DEC
inserts were amplified by PCR using primers designed to contain
pCK4 plasmid sequences (in the HA-tag domain) that were linked
to the multicloning site, ACCTAGATCTTACCCATACGATGTTC-
CAG, and the terminator sequence, CGATGCAC AGTTGAAGT-
GAACTTGC, downstream of the multicloning site of pCK4. The
amplified sequences were excised by BglII and EcoRI digestion and
inserted into pEGFP-C1 at the same BglII/EcoRI sites. The green
fluorescence protein (GFP) tag was localized at the N terminus of
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these DEC constructs. For LEF/TCF-dependent transactivation
analysis, cells were transfected with the pCGN-HA expression vec-
tor containing the S33Y b-catenin mutant (Shtutman et al., 1999) and
the TOPFLASH and FOPFLASH luciferase reporter vectors (van de
Wetering et al., 1997), as previously described (Zhurinsky et al.,
2000b). A b-galactosidase–expressing vector was cotransfected as
an internal control for transfection efficiency. After 24 h, the cells
were lysed, and both luciferase and b-galactosidase activities were
determined by enzyme assay kits (Promega, Madison, WI). For
Western blots and immunoprecipitations, cells were harvested 24 h
after transfection and lysed in either Laemmli’s sample buffer or
immunoprecipitation buffer (see below), respectively.
Immunoblotting and Immunoprecipitation
Equal amounts of total protein from the different transfected cells
were separated by SDS-PAGE and subjected to Western blotting
using the following antibodies: monoclonal anti-HA (clone 12CA5;
Boehringer Mannheim, Indianapolis, IN), polyclonal anti-HA (a gift
from M. Oren, Weizmann Institute of Science, Rehovot, Israel),
polyclonal anti-b-catenin (Sigma, St. Louis, MO), and monoclonal
anti-GFP antibody (Roche Molecular Biochemicals, Burlington, NC).
For coimmunoprecipitation, cells transfected with the GFP-DEC
constructs and the S33Y b-catenin were lysed in immunoprecipita-
tion buffer containing 20 mM Tris-HCl, pH 8.0, 1% Triton X-100, 140
mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM MgCl2, 1 mM
dithiothreitol, 1 mM sodium orthovanadate, and 50 mg/ml phenyl-
methylsulfonyl fluoride. Equal amounts of protein were incubated
with 2 ml of polyclonal anti-b-catenin antibody and 20 ml of protein
A/G-agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) for
4 h at 4°C. The beads were washed five times with 20 mM Tris-HCl
buffer, pH 8.0, containing 150 mM NaCl and 0.5% Nonidet P-40, and
the immune complexes were recovered by boiling in Laemmli’s
sample buffer and resolved by SDS-PAGE. To detect the coprecipi-
tated GFP-DEC constructs, the blots were incubated with anti-GFP
antibody. Blots were developed using the ECL method (Amersham,
Figure 1. Mapping the minimal binding
site on DEC cytoplasmic tail for b-catenin
(bcat) and Arm using the yeast two-hy-
brid (2 hyb) system. (A) Schematic repre-
sentation of the DEC derivatives used in
our analyses, with ability to bind Arm/b-
catenin in either yeast or mammalian cells
summarized in the right-hand columns.
TM, transmembrane; TC, tissue culture.
*Data from Pai et al. (1996). (B) Sequence
of the minimal binding region of DE-cad-
herin, with the boundaries of the smallest
DEC derivatives indicated. (C) All of the
DEC derivatives bind to both fragments of
Arm and b-catenin in yeast. The full-
length DE-cadherin cytoplasmic domain
(DEC), or smaller derivatives of DEC (di-
agrammed in A and B), fused to the Gal4
transcriptional activation domain, were
transformed into yeast cells along with
portions of Arm or b-catenin fused to the
LexA DNA-binding domain. Average
b-galactosidase values are shown for each
DEC derivative together with the full Arm
repeat region of Arm or b-catenin (Arm
R1–12 or bcat R1–12, left), or a smaller
fragment of the Arm repeat region (Arm
R2–10 or bcat R2–10, right). 0, background
level of b-galactosidase activity with no
DEC fragment fused to Gal4. **DEC 25
was tested against only Arm R1–12. Its
b-galactosidase value was 14.4 U, com-
pared with 18.3 U for the negative control.
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Arlington Heights, IL). Autoradiograms were scanned with a GS-
700 imaging densitometer (Bio-Rad, Hercules, CA) and quantitated
using the FotoLook PS 2.07.2 software. The intensity of the bands
was quantitated using the National Institutes of Health image 1.61
software.
Immunofluorescence Microscopy
Cells were cultured on glass coverslips, fixed with 3% paraformal-
dehyde in phosphate-buffered saline, and permeabilized with 0.5%
Triton X-100. Monoclonal or polyclonal antibodies to b-catenin were
used to label the endogenous b-catenin. The secondary antibodies
were Cy3 goat anti-mouse or anti-rabbit immunoglobulin G (Jack-
son ImmunoResearch Laboratories, West Grove, PA). The trans-
fected GFP-DEC constructs were detected in the fluorescein isothio-
cyanate channel. The samples were visualized using an Axiovert
S100 microscope (Zeiss, Germany).
RESULTS
Mapping the Minimal Arm/b-Catenin–interacting
Region of DE-Cadherin
The binding site for Arm on the DE-cadherin cytoplasmic
tail was previously mapped to the C-terminal portion of the
cadherin tail (Pai et al., 1996). To determine the minimum
region essential for binding, we first used the yeast two-
hybrid system to assess binding between the Arm repeat
region of both Arm and b-catenin and smaller fragments of
the DE-cadherin tail (Figure 1). A series of fragments, rang-
ing in size from 23–34 amino acids, were tested, and all
bound both Arm and b-catenin as assessed by the two-
hybrid system (Figure 1C).
We then examined whether these minimal binding frag-
ments, when fused to GFP at their N termini, retained the
ability to interact with b-catenin in mammalian cells. To do
so, we made use of several assays. First, we assessed the
ability of the GFP–DE-cadherin tail and its fragments to
coimmunoprecipitation with b-catenin (Figure 2A). Second,
we tested the ability of these fragments to block the interac-
tion of b-catenin with endogenous LEF/TCF, as measured
by their ability to block LEF/TCF-mediated transactivation
(Figure 2B). Finally, we assessed the capacity of these frag-
ments to block the interaction of b-catenin with endogenous
APC or axin, thus stabilizing b-catenin by blocking its tar-
geting to the proteasome (Figure 2C). These assays generally
paralleled the results in the yeast two-hybrid system (Figure
1C). One difference was noted however: whereas DEC28,
which is 27 amino acids in length, binds by all three assays
to b-catenin (Figures 1), DEC27 and DEC29, the smallest
constructs that bound Arm and b-catenin in yeast (Figure 1,
A and C), failed to detectably coimmunoprecipitate with
b-catenin (Figure 2A) and also failed to block LEF/TCF-
mediated gene expression (Figure 2B). DEC27 and DEC29,
which are 4 amino acids shorter than DEC28 at their C
termini (DEC29 also has three extra N-terminal amino ac-
ids), exhibited a reduced ability to stabilize b-catenin, al-
though they retained some activity in this assay (Figure 2C).
A subset of these DEC fragments was also tested for the
effect on endogenous b-catenin localization and levels by
immunofluorescence (Figure 3). Transfection of the control
GFP expression vector into MDCK cells gave a diffuse dis-
tribution of GFP in the cytoplasm and the nucleus, without
affecting the organization of the endogenous b-catenin in the
transfected cells. In contrast, expression of the GFP-tagged
DEC tail in these cells (DEC, Figure 3A) resulted in partial
disruption of adherens junctions and the accumulation of
b-catenin in the cytoplasm and the nuclei (Figure 3B). Ex-
pression of the shorter (30 amino acid) cadherin tail frag-
ment DEC13 in MDCK cells (Figure 3C) resulted in the
accumulation and diffuse distribution of b-catenin (Figure
3D) but without a detectable effect on its organization in
adherens junctions. In contrast, DEC9, which was unable to
bind b-catenin in the assays described above (Figures 1 and
2), had no effect on the accumulation or organization of
endogenous b-catenin in MDCK cells (Figure 3, E and F). It
is noteworthy that DEC13 was positive in Arm/b-catenin
binding in the two-hybrid screen (Figure 1, A and B) and by
coimmunoprecipitation in mammalian cells (Figure 2A) and
effectively protected b-catenin from degradation in 293 cells
(Figure 2C). In CHO cells that express only very low levels
of N-cadherin (and thus do not form adherens junctions),
transfection of DEC (Figure 4A) or DEC13 (Figure 4C)
brought about the accumulation of b-catenin in the nuclei of
these cells (Figure 4, B and D), whereas DEC9 expression
(Figure 4E), as expected, had no effect on the endogenous
b-catenin (Figure 4F). The transfection into MDCK cells of
DEC27 and DEC29 (Figure 3I), which did not bind to b-cate-
nin in the assays described above (Figures 1 and 2), also had
no effect on the subcellular distribution of b-catenin or the
organization of adherens junctions (Figure 3J). In contrast,
DEC28 (which bound to b-catenin in the two-hybrid assay
and coimmunoprecipitation, Figures 1 and 2), when trans-
fected into MDCK cells (Figure 3G), induced the accumula-
tion of the endogenous b-catenin in the cytoplasm and nu-
clei of these cells (Figure 3H).
Defining Amino Acids Critical for the Arm/b-
Catenin–DE-Cadherin Interaction
We next set out to determine which amino acids within the
minimal DE-cadherin–binding region were essential for the
interaction with Arm and b-catenin. Mammalian b-catenin
can bind DE-cadherin both in Drosophila (White et al., 1998;
Cox et al., 1999) and in cultured mammalian cells (see be-
low), and Arm can also bind mammalian E-cadherin (A.
Wodarz and R. Nusse, personal communication). We there-
fore used the comparison of vertebrate and Drosophila cad-
herins to determine candidate residues that might contribute
to binding. Based on comparisons of the Arm-binding
regions of cadherin, APC, and TCF family members, we
focused on acidic and serine/threonine residues, although
we also mutated other conserved amino acids. Although we
focused on residues within the minimal binding region, we
introduced our mutations in the context of the full-length
DE-cadherin tail, thus mimicking the situation in vivo.
We began with three clustered point mutations that each
change three or four nearby residues in different regions of
the minimal binding site to alanine (Figure 5A). DECM1
altered four conserved serine residues in the center of the
minimal binding region, DECM2 altered four conserved
amino acids including one acidic residue in the N-terminal
part of the minimal binding region, and DECM3 altered
three conserved acidic residues (aspartates) in the C-termi-
nal part of the minimal binding region (Figure 5A). Surpris-
ingly, none of these mutations significantly affected binding
to the full-length Arm repeat region of either Arm or b-cate-
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Figure 2. Analysis of the ability of different
fragments of the DEC cytoplasmic tail to in-
teract with b-catenin, affect its stability, and
inhibit b-catenin–mediated transactivation.
(A) The ability of selected GFP-DEC deriva-
tives to coimmunoprecipitate with cotrans-
fected HA-tagged b-catenin was determined
by immunoprecipitation (IP) from 293T cells
transfected with HA-tagged b-catenin and
GFP-tagged DEC constructs with anti-GFP
antibody, followed by Western blotting with
anti-HA antibody. The total level of trans-
fected b-catenin and DEC constructs was de-
termined by immunoblotting (IB) with anti-
HA-antibody. (B) 293T cells were transfected
with GFP-tagged derivatives of the DEC cy-
toplasmic tail (DEC) or the full-length mam-
malian E-cadherin tail (E), along with b-cate-
nin (b), a LEF/TCF reporter plasmid (T), and
Lac Z. Luciferase activity was determined
from duplicate plates as fold activation after
normalizing for transfection efficiency by
measuring b-galactosidase activity. T, cells
were transfected with the reporter plasmid
alone; V, cells transfected with the reporter
plasmid, HA-tagged b-catenin and the GFP-
vector used for the construction of the cad-
herin derivatives. (C) The cadherin deriva-
tives used in B were transfected into CHO
cells, and their ability to protect the endoge-
nous b-catenin from degradation was deter-
mined by analyzing the level of b-catenin
expressed in the DEC mutant-transfected
cells by Western blotting with anti-b-catenin
antibody. The level of expression of DEC con-
structs was determined by immunoblotting
with an antibody against the GFP tag. Quan-
titation of the b-catenin level expressed in
CHO cells was carried out by normalizing the
intensity of the b-catenin bands shown to
those of the DEC band for each derivative.
Analysis of Cadherin-b-Catenin Binding
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nin in the two-hybrid system (Figure 5B, left). Because Arm
repeats 3–8 retain the ability to bind several of Arm’s part-
ners (Pai et al., 1996), we reasoned that such shorter Arm
fragments might be compromised in binding to DE-cadherin
derivatives and thus might be more sensitive to mutational
changes. We therefore tested the DECM1-DECM3 mutants
for their capacity to bind to Arm repeats 2–10 of both Arm
and b-catenin (Figure 5B, right). In this assay, there was a
substantial reduction in the binding of DECM2 to both Arm
and b-catenin, whereas the other two mutations (DECM1
and DECM3) did not substantially affect binding (Figure 5B,
right). These data suggested that DECM2 might weaken
binding but not enough to be detectable in the context of the
full-length DE-cadherin tail binding to the full-length Arm
repeat region. Interactions outside the minimal Arm-binding
region may normally help stabilize this association and thus
could partially compensate for mutations such as DECM2.
We therefore introduced the DECM2 mutation into a 34-
amino acid peptide centered on the minimal binding region
Figure 3. The effect of DEC cytoplasmic domain derivatives on the
organization of adherens junctions and subcellular distribution of
b-catenin (b-cat). MDCK cells were transfected with various GFP-
tagged DEC derivatives (diagrammed in Figure 1, A and B), and the
distribution of the GFP-tagged DEC derivatives (A, C, E, G, and I)
and of the endogenous b-catenin (B, D, F, H, and J) was determined
by double fluorescence microscopy using rhodamine-labeled anti-
b-catenin antibody. Bar (in A), 10 mm. Note the reduction in junc-
tional b-catenin in DEC-expressing cells but not in cells transfected
with other DEC constructs. Also note that DEC9 and DEC29 do not
increase the endogenous b-catenin level, whereas DEC13 does.
Figure 4. Analysis of the ability of DEC derivatives to increase
the level and the accumulation of endogenous b-catenin (b-cat) in
the nucleus. Some of the GFP-DEC constructs described in Figure
3 were transfected into CHO cells (A, C, and E), and their ability
to elevate the endogenous b-catenin and induce its translocation
into the nucleus (B, D, and F) was determined by double fluores-
cence as described in Figure 3. Bar in (A), 10 mm. The arrows mark the
transfected cells. Note that, whereas DEC13 and DEC induced the
accumulation of endogenous b-catenin in the nucleus, DEC9 was un-
able to do so.
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(DEC30; Figure 1A). In this context (rather than in the full-
length DEC tail), the DECM2 mutation essentially abolished
binding to even the full-length Arm repeat region
(DEC30(M2); Figure 5B).
Next, we tested this same set of mutants for binding to
b-catenin in cultured mammalian cells, using the assays
described above. Both DECM1 and DECM3 retained sub-
stantial ability to block TCF-directed gene expression
(Figure 6A), suggesting that they could block binding of
b-catenin to TCF family members. All three mutants were
reduced in their ability to stabilize b-catenin (Figure 6B),
although all appear to retain a small amount of activity in
this assay. Finally, the overexpression of DECM3 in
MDCK cells (Figure 6C) resulted in the accumulation of
b-catenin in the cytoplasm and nuclei of these cells (Fig-
ure 6D).
In addition to these mutations, we also analyzed three
mutants with more substantial changes in the minimal bind-
ing region. Mutant DECM7 combined the changes found in
DECM1 and DECM2 and also mutated an additional amino
acid, aspartic acid 1450, to valine (Figure 5A). Mutant
DECM8 altered all of the serine and threonine residues in
the core of the binding site to alanine (Figure 5A) and also
altered the semiconserved residue glycine 1455 to aspartic
acid. A subset of these residues is a likely target of phos-
phorylation in vivo (Stappert and Kemler, 1994). Finally, in
DECM10, 20 amino acids were deleted in the core of the
minimal binding region (Figure 5A). When tested against
the full Arm repeat region of Arm or b-catenin in the two-
hybrid system, DECM7 and DECM10 were essentially inac-
tive (Figure 5B). In contrast, DECM8 had little effect on
binding to the entire Arm repeat region (Figure 5B, left),
although it did reduce binding to Arm repeats 2–10 of both
Arm and b-catenin (Figure 5B, right). We also analyzed an
additional mutant, DECM9, in which four of the conserved
serine residues were changed to glutamic acid (Figure 5A).
These serine residues are phosphorylated in vivo, and in
some cases, this change mimics phosphorylation. DECM9
retained full ability to bind both Arm and b-catenin in the
two-hybrid assays (Figure 5B).
We then studied the interaction of this set of mutants with
b-catenin in mammalian cells. In this setting, DECM7,
DECM8, and DECM10 all abolished interaction completely,
losing both the ability to block TCF/LEF-dependent gene
expression (Figure 6A) and to stabilize b-catenin (Figure 6B).
The expression of M8 in MDCK cells (Figure 6E) had no
effect on adherens junctions or on b-catenin organization
(Figure 6F). In contrast, DECM9 preserved the capacity to
interact with b-catenin, because it very efficiently protected
it from degradation (Figure 6C) and inhibited LEF/TCF-
directed transactivation (Figure 6A), in line with the two-
hybrid assays. This is in striking contrast to DECM1, in
which the same serine residues were changed to alanine
rather than glutamic acid.
DISCUSSION
b-Catenin/Arm plays key roles in cell-cell adhesion and
Wnt signal transduction. Deregulation of these activities
Figure 5. Analysis of the effect of clustered point
mutations in the minimal Arm-binding domain of
DEC on its ability to bind Arm and b-catenin (bcat)
in the yeast two-hybrid system. (A) Diagram of the
DEC tail and sequences of the clustered point mu-
tations used in this study, with the sequences of
DE-cadherin (DE-Cad) and human E-cadherin (hE-
Cad) in the region of the mutations shown below.
All mutations were introduced into and analyzed in
the context of the full-length cytoplasmic tail. The
mutation DECM2 was also tested in the context of a
smaller fragment of the cadherin tail (DEC30; Figure
1A)—this derivative is DEC30(M2). (B) The DE-cad-
herin mutants diagrammed in A were fused to the
Gal4 transcription activation domain and trans-
formed into yeast cells together with the full Arm
repeat region of Arm or b-catenin (Arm R1–12 or
bcat R1–12, left) or a smaller fragment of the Arm
repeat region (Arm R2–10 or bcat R2–10, right),
fused to the LexA DNA-binding domain. Average
b-galactosidase activities are shown.
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Figure 6. Analysis of the effect of clustered
point mutations in the minimal Arm-binding
domain of DEC on its capacity to interact
with b-catenin, protect it from degradation,
inhibit b-catenin/LEF-mediated transactiva-
tion, and affect b-catenin organization. (A)
The ability of clustered point mutations (dia-
grammed in Figure 5A) to affect b-catenin/
LEF-1–mediated transactivation in 293T cells
was examined as described in Figure 2B. (B)
The ability to protect b-catenin from degra-
dation was examined in CHO cells, and the
levels of b-catenin were quantified as de-
scribed in Figure 2C. Because the samples
were originally analyzed on the same gel
with the samples shown in Figure 2C, the
control samples (V, DEC, and D9) are shown
again. (C–F) MDCK cells were transfected
with GFP-tagged DECM3 (C, M3) and
DECM8 (E, M8), and the organization of the
endogenous b-catenin (b-cat) in the respec-
tive samples (D and F) was determined by
double fluorescence microscopy. Bar, 10 mm.
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can lead to disease. Activation of b-catenin–mediated sig-
naling contributes to a wide variety of human tumors
(reviewed by Zhurinsky et al., 2000a), and dysfunction of
cadherin-catenin adhesion is involved in cancer metasta-
sis (reviewed by Christofori and Semb, 1999). b-Catenin/
Arm mediates these distinct processes by forming a scaf-
fold upon which different multiprotein complexes are
assembled. To unravel b-catenin’s normal functions and
the alterations in its function in disease, a detailed under-
standing of its interactions with protein partners is re-
quired. This might facilitate a rational approach to design
inhibitors of these interactions. For example, an effective,
specific inhibitor of the b-catenin–TCF interaction might
have therapeutic potential in cancers in which Wnt sig-
naling is activated.
We used the cadherin/b-catenin interaction as a model
for investigating this question. We previously found that
71 amino acid derivatives of the cytoplasmic tail of ver-
tebrate N- or E-cadherin inhibit b-catenin/TCF-mediated
transactivation when introduced into human colon cancer
cells (Sadot et al., 1998; Simcha et al., 1998). Moreover,
expression of the N-cadherin tail in human colon cancer
cells inhibited the elevated transcription of cyclin D1
(Shtutman et al., 1999), thus potentially suppressing its
oncogenic function. In the present study, we analyzed the
interaction between DE-cadherin and b-catenin/Arm in
detail, using several assays, each of which provided dif-
ferent measures of binding. Using the yeast two-hybrid
system, we assessed interaction in the absence of most, if
not all, of b-catenin/Arm’s normal partners, because
yeast lack b-catenin, cadherins, TCFs, APC, and axin.
Furthermore, kinases and other proteins that regulate
interactions between b-catenin/Arm and its partners, are
also likely absent. We also used several assays in mam-
malian cells, which, in contrast to yeast, possess both a
full (or nearly full) complement of b-catenin partners and
the normal set of regulatory machinery that modulates the
interaction between b-catenin and its partners. This diver-
sity of assays allowed us to discriminate among the bind-
ing abilities of cadherin mutants in a more detailed way
than was possible in most previous studies of b-catenin/
Arm interaction with other partners, which, for the most
part, relied on single assays.
Using these assays, we found that quite small fragments
of DE-cadherin, including the 23-amino acid DEC27, bind
both b-catenin and Arm in yeast. In cultured mammalian
cells the criteria for interaction were more stringent. The
smallest DE-cadherin peptide that interacted in mamma-
lian cells was DEC28, which is 27 amino acids in length.
This difference may reflect the fact that in mammalian
cells DEC fragments must compete with endogenous part-
ners for binding—weakened interactions might prevent
effective competition. Alternately, it may simply reflect
differences in the fusion proteins used in each assay. It is
noteworthy, however, that the binding of short DEC frag-
ments, such as DEC28 in mammalian cells, is weaker than
binding of the full cytoplasmic tail of DE-cadherin or
mammalian E-cadherin, as assessed by their ability to
inhibit transcriptional activation by b-catenin (Figure 2B).
Our mutational analysis also revealed critical amino
acids in cadherin required for interaction with b-catenin.
The b-catenin/Arm-binding site is highly conserved
among all classical cadherins. Most of our mutations in
conserved residues had parallel effects in yeast and mam-
malian cells. For example, mutation of three acidic amino
acids near the C terminus of the minimal binding region
(DECM3) had little effect on either binding in yeast or the
ability to block TCF-mediated transactivation, whereas
mutation of four more N-terminal conserved residues
(DECM2) resulted in a detectable reduction in binding in
yeast and a substantial reduction in the ability to block
TCF-mediated transactivation. The most extensive muta-
tions, DECM7 and DECM10, completely blocked the bind-
ing in all assays.
Surprisingly, the serine residues in the binding site,
mutated in DECM1 and DECM8, were largely dispensable
for binding in yeast. In contrast, these mutations impaired
or eliminated the ability to block TCF-mediated transac-
tivation and to stabilize b-catenin in mammalian cells.
One possible explanation for these differential effects is
that these serines are phosphorylated in mammalian cells
(Stappert and Kemler, 1994; Lickert et al., 2000); this may
strengthen binding. Consistent with this possibility, mu-
tation of the four conserved serines to glutamic acid (mu-
tant DECM9), which may mimic phosphorylation, did not
block binding to b-catenin in mammalian cells. In fact,
DECM9 very effectively protected b-catenin against deg-
radation (Figure 2C), in agreement with recent studies by
Lickert et al. (2000). If, in yeast, the relevant kinase(s) are
absent, mutation of these serines would not affect binding.
While this paper was under review, two studies ap-
peared that complement our data. Graham et al. (2000)
solved the structure of b-catenin bound to XTcf3, thus
revealing in full detail how b-catenin binds to one of its
partners. XTcf3 binds in the groove on the surface of
b-catenin, with the XTcf3 peptide forming a b-hairpin at
its N terminus and an a-helix at its C terminus, with an
extended peptide in between. From this structure and
parallel mutagenesis of b-catenin, they identified two key
charge-charge interactions between b-catenin and the ex-
tended XTcf3 peptide and a key hydrophobic interaction
of b-catenin with the a-helix of XTcf3. They also assessed
the ability of cadherin to bind to their b-catenin mutants
and, from this, proposed a model for how cadherins bind
b-catenin.
Based on our data, we extended this model, as shown in
Figure 7A. In addition to the sequence similarity noted by
Graham et al. (2000) in the extended peptide region, we
suggest a further sequence alignment in the a-helical
region. Notably, the three XTcf3 residues, which they
identified as critical for interaction with b-catenin, are
conserved in diverse cadherins (boxed in Figure 7A). Al-
though the spacing between the extended peptide and the
a-helix differs between TCF and cadherins, this region of
XTcf3 is disordered in the structure and may form a
flexible loop, and if fully extended, the cadherin peptide
could span the gap. We also noted a similar, although less
striking, alignment of the 20 amino acid repeats of APC
and XTcf3, with all three key residues also conserved
(Figure 7B).
Our mutational analysis can also be examined in light of
this structure (Figure 7A). Mutation DECM2, which has a
severe effect on binding, alters four amino acids including
a glutamic acid predicted by analogy to XTcf3 to mediate
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one of the key charge-charge interactions with b-catenin
(Figure 7A, bold underline). In contrast, mutation
DECM3, which had no effect in yeast and the least severe
effect in mammalian cell assays, maps to a region pre-
dicted by analogy to be outside the structured portion of
the binding site (Figure 7A, italics). The analysis of mu-
tations DECM1 and DECM9 is more complex. Mutation of
the four serines targeted in DECM1 to alanine has no
effect in yeast but substantially reduces binding in mam-
malian cells. In contrast, mutation DECM9, which altered
these serines to glutamic acid, did not affect binding. Of
these four serines, the second and third align with serines
in XTcf3. The second serine is predicted to be on the face
of the a-helix away from b-catenin, whereas the third
serine does not contribute to binding. The first serine is a
valine in XTcf3, which participates in hydrophobic con-
tacts, whereas the fourth serine is predicted by analogy to
XTcf3 to be beyond the end of the a-helix and to have its
side chain pointed away from b-catenin. If, as discussed
above, these serines are phosphorylated, then the first and
third phosphoserines might make charge-charge interac-
tions with lysine 292 of b-catenin; this would also be the
case if they were mutated to glutamic acid.
von Kries et al. (2000) also revealed new insights into
b-catenin’s interaction with its partners. They mu-
tagenized b-catenin to identify amino acids in the Arm
repeat region, which are essential for binding to APC,
axin/conductin, and TCF/LEF. They found that muta-
tions mapping to distinct Arm repeats blocked binding to
individual partners. Thus, LEF-1 binding was inhibited by
mutations in Arm repeat 8, whereas conductin binding
was inhibited by mutations in Arm repeats 3 and 4. These
data suggest that either different partners bind to distinct
sites on b-catenin or, if the binding sites coincide, different
subsets of the contacts between b-catenin and each its
partners provide most of the free energy of binding. In
parallel, they also examined whether these b-catenin mu-
tations affected binding to E-cadherin (J.P. von Kries and
W. Birchmeier, personal communication). In contrast to
their results with the other partners, none of the muta-
tions specifically blocked b-catenin binding to cadherin.
Graham et al. (2000) also tested mutant forms of b-catenin
for binding to XTcf3, C-cadherin, APC, and axin. XTcf3
binding required two key charge-charge interactions with
the extended peptide region and a key hydrophobic in-
teraction with the a-helix. For cadherin, mutations pre-
dicted from the structure to block the key charge-charge
interactions reduced binding, but mutations in the a-he-
lix– binding region had little effect. These data are of
interest in relation to the present study in which, contrary
to expectations, none of the first series of clustered point
mutations (DECM1, DECM2, and DECM3) abolished DEC
binding to b-catenin in yeast. One possible explanation
for all these results is that the binding of cadherins to
b-catenin differs from that of the other partners, with
strong contacts made throughout the binding region.
Thus, point mutations in either cadherin or b-catenin
would have a lesser effect on binding. This might also
explain the apparently higher affinity of cadherin for Arm
in vivo, as assessed by competition for the limiting pool of
Arm present in arm mutant embryos (Cox et al., 1996).
We assessed our mutations in the full DE-cadherin cy-
toplasmic tail. We also assessed DECM2 in a second con-
text, introduced into a 34-amino acid fragment centered
on the minimal binding region. In this context, DECM2
had a much more severe effect on b-catenin binding in
yeast than it did when present in the full DE-cadherin tail.
This result is consistent with the possibility that b-catenin
binding is stabilized by interactions with regions of the
cadherin tail outside the minimal binding domain or that
the entire tail folds into a conformation that facilitates
b-catenin binding.
Figure 7. A model for the struc-
ture of the b-catenin-binding re-
gion of cadherin. (A) The se-
quence of Xenopus Tcf3 (XTcf3)
and Drosophila TCF (dTCF) are
aligned below a diagrammatic
representation of the structure of
XTcf3 as determined by Graham
et al. (2000). A b-hairpin motif is
indicated by “b -..” Identical
residues are indicated by vertical
lines and similar residues are in-
dicated by colons. Below is a pro-
posed alignment of Drosophila E-
cadherin (DE-cad) and mouse
E-cadherin (mE-cad) with the ex-
tended peptide and a-helical re-
gions of XTcf3. A consensus is
displayed at the bottom positions
(where at least three fourths of
the sequences match). The three
residues that are key for XTcf3
binding to b-catenin are boxed,
and all are conserved in all sequences. The amino acids altered in mutation DECM2 (YEG G), which have a strong effect on DEC binding
to b-catenin/Arm in our assays, are bold and underlined. The amino acids altered in mutation DECM3 (DD D), which had the weakest
effect on binding, are shown in italics. The serines altered in mutations DECM1 and DECM9 are in italics and underlined. (B) Alignment of
the XTcf3 sequence and structure with four 20-amino acid repeats of Drosophila APC (dAPC).
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To affect one function of b-catenin without affecting the
others, one must design inhibitors that specifically inter-
fere with a particular protein-protein interaction. Our
results provide some insight into this issue. Both wild-
type and mutant cadherin peptides were more effective in
blocking interaction of endogenous b-catenin with TCF/
LEF than in blocking interactions between endogenous
b-catenin and the axin/APC complex or assembly of ad-
herens junctions. This would be the desired outcome for a
specific inhibitor that blocked the oncogenic action of
b-catenin. Our data also suggest possible peptide candi-
dates for cocrystallization of cadherin and b-catenin.
When combined with the b-catenin–TCF structure, this
would set the stage for initiating the design of synthetic
inhibitors of different protein-protein interactions, which
can be tested in cell culture and animal models for efficacy
in blocking Wnt signaling or modulating cell adhesion
and cancer progression.
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